	US 12,156,917 B2
	CNP prodrugs with carrier attachment at the ring moiety
Harald Rau, Dossenheim (DE); Ulrich Hersel, Heidelberg (DE); Felix Cleemann, Mainz (DE); and Kennett Sprogøe, Holte (DK)
Assigned to ASCENDIS PHARMA GROWTH DISORDERS A/S, Hellerup (DK)
Filed by ASCENDIS PHARMA GROWTH DISORDERS A/S, Hellerup (DK)
Filed on Jun. 16, 2022, as Appl. No. 17/842,436.
Application 17/842,436 is a division of application No. 16/067,095, granted, now 11,413,351, previously published as PCT/EP2017/050209, filed on Jan. 5, 2017.
Claims priority of application No. 16150625 (EP), filed on Jan. 8, 2016; application No. 16179288 (EP), filed on Jul. 13, 2016; and application No. 16191460 (EP), filed on Sep. 29, 2016.
Prior Publication US 2022/0331438 A1, Oct. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/60 (2017.01); A61K 38/22 (2006.01); A61P 19/08 (2006.01)

CPC A61K 47/60 (2017.08) [A61K 38/22 (2013.01)]

13 Claims

1. A method of treating achondroplasia, hypochondroplasia, short stature, Noonan syndrome or short stature homeobox-containing gene (SHOX) deficiency in a mammalian patient in need thereof, comprising the step of administering to said patient a therapeutically effective amount of a C-type natriuretic peptide (CNP) prodrug or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition comprising a CNP prodrug or a pharmaceutically acceptable salt thereof and at least one excipient, wherein the CNP prodrug or pharmaceutically acceptable salt thereof comprises

a CNP moiety -D comprising a ring moiety having the sequence of SEQ ID NO:96; and

a carrier moiety -Z that is conjugated through a moiety -L²- to a reversible prodrug linker moiety -L¹-, which reversible prodrug linker moiety -L¹- is covalently and reversibly conjugated to a side chain of an amino acid residue of said ring moiety of -D or to the backbone of said ring moiety of -D; and wherein -L²- is a chemical bond or a spacer.